

2nd Joint Meeting on
Lipid, Lipoproteins
and **Hypolipidaemic Therapy**

9 - 11 October 2015
Kos, Greece

Kos International Convention Center (KICC)

Jointly organized by the:



**EUROPEAN
ATHEROSCLEROSIS
SOCIETY**



**HELLENIC
ATHEROSCLEROSIS
SOCIETY**



**TURKISH
SOCIETY OF
CARDIOLOGY**



FINAL PROGRAMME

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Lerpur® δισκία επικαλυμμένα με λεπτό υμένιο 20mg & 40mg. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ ΣΕ ΔΡΑΣΤΙΚΟ ΣΥΣΤΑΤΙΚΟ: Lerpur® δισκία 20mg: Κάθε δισκίο περιέχει 20mg σιμβαστατίνης. Lerpur® δισκία 40mg: Κάθε δισκίο περιέχει 40mg σιμβαστατίνης.

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.



ADRIANALIN
PHARMACEUTICALS

LEPUR[®]

simvastatin

30 δισκία

ΕΠΩΝΥΜΟ
ΕΛΛΗΝΙΚΟ
ΦΑΡΜΑΚΟ

Με την εγγύηση της



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ

Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής, Τηλ.: 210 6039326-9, Fax: 210 6039300

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ

Σεβαστείας 11, 115 28 Αθήνα, Τηλ.: 210 7488711, Fax: 210 7488731

Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη, Τηλ.: 2310 459920-1, Fax: 2310 459269

PCSK9: μια πρωτεΐνη- κλειδί στην κατανόηση του μεταβολισμού της LDL-C

Η ανακάλυψη της PCSK9, μιας πρωτεΐνης η οποία παίζει σημαντικό ρόλο στην ικανότητα του οργανισμού να ρυθμίζει τα επίπεδα της LDL-C, ανοίγει το δρόμο για μια εντελώς καινούργια στρατηγική αντιμετώπισης της υψηλής χοληστερίνης.

PCSK9 

PCSK9

GR-ALL15.03.01

Lagace TA et al. J Clin Invest. 2006;116:2995-3005.

Η Sanofi και η Regeneron συνεργάζονται με στόχο τη βελτιστοποίηση της διαχείρισης της υπερχοληστερολαιμίας, διερευνώντας τις ανάγκες των ασθενών με μη ικανοποιητικά ρυθμισμένα LDL-C.

Sanofi-aventis A.E.B.E. Λεωφ. Συγγρού 348, Κτήριο Α'
17674 Καλλιθέα. Τηλ.: 210 90 01 600, Fax: 210 92 49 088
www.sanofi.gr

SANOFI 

Table of Contents

Welcome	5
Organization	6-7
Guidelines for Invited Faculty & Presenting Authors	8-9
Scientific Programme	
Friday, October 9 th , 2015	10-11
Saturday, October 10 th , 2015	12-13
Sunday, October 11 th , 2015	14-16
Invited Faculty	17-18
General Information	19-20
Oral & Poster Presentations	
- Information	21-22
- List	23-33
Sponsors/Acknowledgements	34



Welcome

Dear colleagues, dear friends,

It is our great pleasure to welcome you to the **2nd Joint Meeting on Lipid, Lipoproteins and Hypolipidaemic Therapy**, which is jointly organized by the **European Atherosclerosis Society**, the **Turkish Society of Cardiology** (Working Group on Lipids) and the **Hellenic Atherosclerosis Society** and will be held from **Friday, October 9th to Sunday October 11th, 2015** in **Kos International Convention Center (KICC)**, Greece.

Committed to its aim, the meeting is formed to be attractive and towards the needs of young researchers-trainees, appropriate to share knowledge and experience on current evidence. It will give participants the opportunity to learn and keep updated from invited renowned experts.

This year the Island of Kos has been selected to host this international meeting and we hope that it would be scientifically rewarding and personally memorable for all delegates.

We cannot be but grateful to the European Atherosclerosis Society & the Turkish Society of Cardiology for their support, to all those who worked for the organization and realization of the meeting, to all invited faculty.

We hope that this experiment (started last year with the 1st Joint Meeting) will keep on focusing on a single goal: to make this Joint meeting a leading scientific forum open to friendships and collaborations, that will gain worldwide warm acceptance and recognition for its scientific merit.

Thank you for being here with us in Kos.
Enjoy your stay!

On behalf of the Organizers
Alexandros Tselepis
President of the
Hellenic Atherosclerosis Society

Organization

Jointly Organized by the:



**EUROPEAN
ATHEROSCLEROSIS
SOCIETY**

[\(http://www.eas-society.org/\)](http://www.eas-society.org/)

Executive Committee:

President Alberico L. Catapano

Vice President Olov Wiklund

Past President Olov Wiklund

Secretary & Award Committee Chair Petri Kovanen

Treasurer Jan Borén

Committee Members Geesje Dallinga-Thie

Børge Nordestgaard

Arnold von Eckardstein

Michal Vrablík

Adjunct Committee Members

Advisor in Matters related to Congress Marja-Riitta Taskinen

Advisor in Matters related
to National Society Relations Zeljko Reiner

Advisor in Scientific Matters Bart Staels

Educational Activities Committee Chair Lale Tokgözoğlu

Advisor in Matters related to
European Union Relations/Contacts Maciej Banach

**HELLENIC
ATHEROSCLEROSIS
SOCIETY**

(<http://www.atherosclerosis.gr/>)

The Board of Directors, which assembled after the June 2014 elections, is composed of the following members:

President	Alexandros Tselepis
Vice President	Christos Pitsavos
General Secretary	Vassilios Nikolaou
Secretary for the Working Groups	Konstantinos Tziomalos
Treasurer	Eleni Bilianou
Members	Vassilios Athyros Emmanouil Ganotakis Moses Elisaf Vassilios Kotsis Evangelos Liberopoulos Christina Chrysohoou

**TURKISH
SOCIETY OF
CARDIOLOGY**

(<http://www.tkd.org.tr/>)

The Board of Directors held by election at the General Meeting on May 10th, 2014:

President	Sadberk Lale Tokgözoğlu
President Elect	Mahmut Şahin, FESC
Vice President	Engin Bozkurt
General Secretary	Adnan Abacı
Secretary	Enver Atalar
Treasurer	Mehmet Sıddık Ülgen
Board Members	Sinan Aydoğdu Merih Kutlu Necla Özer

Lipid Working Group:

President	Meral Kayıkçıoğlu
Past President	Bülent Behlül Altunkeser
Members	Remzi Yılmaz Öner Özdoğan Ceyhun Ceyhan

Guidelines for Invited Faculty & Presenting Authors

A. For PPT Presentations (*applies to all presenters*)

Formal Requirements

Language: All presentations have to be given in **English** (as the official language of the meeting is English and no simultaneous translation will be provided).

Advertising: Advertising of products is **prohibited**. Be sure your slides are free of any commercial bias (eg company names or logos).

Patient anonymity: Kindly make sure that no patient names or any other information allowing the identification of a patient appear in your presentation.

Copyright reserved: It is the author's responsibility to ensure that any part of the slide show (figures, tables, images, etc.) is free of any third party right.

Technical Requirements

- Preparation

Format: preferable format is MS PowerPoint (ppt or pps).

Macintosh presentations will be accepted.*

Versions: up to MS PowerPoint 2010.

Saving of files: For onsite upload, the presentation has to be saved on a USB flash (recommended), CD-ROM or DVD-ROM.

Video clips: If you are using embedded video clips in your presentation, please remember to also have the video clips in a separate file (not only in the presentation).

Fonts & character: To avoid any possible compatibility problems, it is preferable not to use any special fonts or special characters.

****To the attention of Mac users:***

Please make sure to come with the suitable adapter and to also have a backup PPT for PC.

You are kindly requested to meet with the technical support personnel at least **two (2) hours before the beginning of the session**, in order to assure compatibility (or backup solutions).

- Onsite presentation

You are kindly requested to deliver your presentation(s) to the technical support personnel at least **one (1) hour before the beginning of the session** (in order to ensure on time they run smoothly and to be able of making any possible changes). If the presentation is scheduled early in the

morning, you are kindly requested to check your presentation with the technical support personnel the day before.

Your PPT presentation will be made available in the lecture hall via computer network. There will be no possibility to connect your personal laptop in the lecture hall, due to very restricted timeslots (row of the presentations).

The Hall will be equipped with the following:

• LCD projector with remote control (operated by presenter-a mouse will be also available) • Screen & Lighted pointer • Podium mounted microphone • Audience aisle microphones

B. Time Slots

It is very important to respect the flow of the session and the exact time available for each presentation and therefore you are requested to be consistent with the time slots. It is advisable to rehearse your presentation prior to the congress to ascertain that the **time is not exceeded**.

As a chairman or Moderator, you should ensure the smooth progress of the session, time management as well as encourage discussions and interactions between faculty members and the audience by allowing sufficient time for questions from the audience.

C. Conflict of Interest Disclosure (*applies to all invited faculty*)

In compliance with UEMS guidelines, speakers/chairmen are **strictly requested** to disclose or indicate potential conflicts of interest (with sponsors) that might cause a bias.

Therefore you **are requested (if not already done) to:**

1. Get advised by the sponsors list
2. Declare any potential or actual conflict of interest regarding the above sponsors and topics of the presentation (s)
 - at the Second Slide of your PowerPoint Presentation (if speaker)
 - or orally at the beginning of the session (if chairman etc)

The existence of potential conflicts of interest does not necessarily indicate a bias. However it is your ethical obligation to inform organizers and participants so that they are made aware of any relationship with the sponsors that might cause unintentional bias. A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, funding for research, investments, family relationship etc.

Scientific Programme

Friday, **October 9th, 2015**

16:00-16:45 **Registration**

16:45-17:00 **Introduction - Welcome Messages**

Alberico Catapano (Italy)

President of the European Atherosclerosis Society

Lale Tokgozoglu (Turkey)

President of the Turkish Society of Cardiology

Meral Kayikcioglu (Turkey)

President of the Working Group on Lipid, Turkish Society of Cardiology

Alexandros Tselepis (Greece)

President of the Hellenic Atherosclerosis Society

17:00-19:00 **Classic and novel approaches for the treatment of atherosclerosis**

Chairmen: **Dimitrios Mikhailidis (UK), Vedat Sansoy (Turkey)**

Established combination therapies for dyslipidaemias

Dimitrios Mikhailidis (UK)

Recent advances in LDL-lowering therapies: Lower is better?

Lessons from the IMPROVE-IT trial

Konstantinos Tziomalos (Greece)

HDL- modifying therapies. Focus on CETP inhibitors

Meral Kayikcioglu (Turkey)

Novel lipid lowering therapies

Alberico Catapano (Italy)

New pharmacologic treatment of obesity

Dimitrios Kiortsis (Greece)

19:00-19:30 **Coffee break - Poster Viewing**

Friday, **October 9th, 2015**

19:30-21:00

Underlying mechanisms of residual cardiovascular risk

Chairmen: **Hakan Kultursay (Turkey),**
Alexandros Tselepis (Greece)

Triglycerides and remnant lipoproteins in cardiovascular risk
Borge Nordestgaard (Denmark)

New insights into the pathophysiological role of Lp(a)
Alexandros Tselepis (Greece)

HDL biology, quantity, quality, and residual risk
Alberico Catapano (Italy)

Non-alcoholic steatohepatitis and cardiovascular risk
Vassilios Athyros (Greece)

21:00

Dinner (*Kipriotis Village Hotel*)

Saturday, **October 10th, 2015**

09:00-09:30

Lecture*Chairman:* **Vassilios Nikolaou (Greece)**

The role of LDL-cholesterol in cardiovascular risk models stratification

Demosthenes Panagiotakos (Greece)

09:30-11:30

Unresolved issues in statin therapy*Chairmen:* **Zeki Ongen (Turkey), Moses Elisaf (Greece)**

Statin and diabetes mellitus. Which is the evidence?

Moses Elisaf (Greece)

Statin and renal function

Vassilios Athyros (Greece)

Statin-fibrate combination therapy. What is the evidence?

Meral Kayiklioglu (Turkey)

Statin intolerance

Lale Tokgozoglu (Turkey)

11:30-12:00

Coffee break - Poster Viewing

12:00-13:30

The future of hypolipidemic therapy*Chairmen:* **Alberico Catapano (Italy),
Nevres Koylan (Turkey)**

Molecular biology and physiology of PCSK9

Gilles Lambert (France)

Hypolipidemic therapy. Unmet needs

Dilek Ural (Turkey)

PCSK9 inhibition: From the bench to the bedside

Evangelos Liberopoulos (Greece)

13:30 -15.30

Light Lunch - Poster viewing

Saturday, **October 10th, 2015**

15:30-16:30 **Poster Viewing**

16:30-17:00 **Coffee break**

17:00-18:00 ***Early Vascular Ageing and atherosclerosis***

Chairmen: **Vassilios Athyros (Greece),
Asterios Karagiannis (Greece)**

Early vascular changes in children and adolescents with
cardiovascular risk factors

Stella Stabouli (Greece)

Microbiota patterns and risk of glucometabolic disease

Peter Nilsson (Sweden)

The role of statins in arterial stiffness and early vascular ageing

Vassilios Kotsis (Greece)

18:00-19:00 ***Case presentations. Interactive discussion with participants***

Chairmen: **Necla Ozer (Turkey),
Emmanuel Ganotakis (Greece)**

Evangelos Liberopoulos (Greece)

19:00-20:00 ***Guidelines for the treatment of hyperlipidemias***

Presenters: **Necla Ozer (Turkey), Christos Pitsavos (Greece)**

20:00-21:00 ***The EAS Familial Hypercholesterolaemia Studies
Collaboration (FHSC)***

Presenter: **Alberico Catapano (Italy)**

21:00 **Dinner** (*Kipriotis Village Hotel*)

Sunday, **October 11, 2015**08:00-09:30 **Short Oral Presentations**

Chairmen: **Alberico Catapano (Italy),
Alexandros Tselepis (Greece)**

PHARMACOKINETICS OF SELF NANO EMULSION DRUG DELIVERY SYSTEMS FOR THE ORAL ADMINISTRATION OF ROSUVASTATIN CALCIUM

¹Hatice Yesim Karasulu, ²Evren Gundogdu, ³Tugce Turgay, ³Ugur Onsel Turk, ³Sebnem Apaydin, ⁴Ilgin Yidirim Sirmsir, ⁴Candeger Yilmaz, ³Ercument Karasulu
¹Ege University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Izmir, Turkey;
²Ege University, Faculty of Pharmacy, Radiopharmacy Department, Izmir, Turkey;
³Ege University ARGEFAR Drug Development and Pharmacokinetic Research Center, Izmir, Turkey;
⁴Ege University, Medicine Faculty, Endocrinology Department, Izmir, Turkey;

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOMO-FH) IN GREECE: EPIDEMIOLOGICAL DATA FROM 34 PATIENTS

E. Drogari, N. Mavroidis, E. Laios, P. Progiias, V. Mollaki
Choremio Research Institute, Metabolic Unit, 1st Department Pediatrics, University of Athens, «Aghia Sofia» Children's Hospital, Athens, Greece;

SWITCH TO ROSUVASTATIN VERSUS ADDITION OF EZETIMIBE IN PATIENTS RECEIVING ATORVASTATIN: EFFECT ON URINE 8-ISOPROSTANE LEVELS

Eleftherios Klouras, Constantinos Tellis, Fotios Barkas, Evangelos Liberopoulos, Moses Elisaf, Alexandros Tselepis
¹Department of Internal Medicine, School of Medicine University of Ioannina, Ioannina, Greece;
²Atherothrombosis Research Centre / Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;

Sunday, **October 11, 2015**

CHOLESTERYL ESTER STORAGE DISEASE IN GREECE: A RARE INBORN ERROR OF METABOLISM PRESENTING WITH DYSLIPIDAIMIA AND LIVER DISEASE

¹E. Drogari, ¹V. Mollaki, ²H. Christomanou, ³K. Stamatelopoulos, ⁴N. Manolaki
¹*Metabolic and Lipid Clinic, 1st Department of Pediatrics, University of Athens, «Aghia Sofia» Children's Hospital, Athens Greece;*

²*Research Center for Lysosomal and Neurodegenerative Disorder, Athens Greece;*

³*Department of Internal Medicine, University of Athens, «Alexandras» General Hospital, Athens, Greece;*

⁴*2nd Department of Pediatrics, NHS, «Aghia Sofia» Children's Hospital, Athens, Greece;*

RISK FACTORS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE IN CHILDREN AND ADOLESCENTS WITH CHRONIC KIDNEY DISEASE: A SINGLE CENTRE PROSPECTIVE STUDY

¹Styliani Drapaniotti, ²George Karapostolakis, ³Varvara Askiti, ²Marina Vakaki,
³Andromachi Mitsioni, ³ Maria Mila, ³Constantinos Stefanidis, ¹ Anastasia Garoufi
¹*Lipid Outpatient Unit, 2nd Department of Pediatrics, Athens University, Greece;*

²*Radiology Department, "P. & A. Kyriakou" Children's Hospital, Athens, Greece;*

³*Unit of Pediatric Nephrology, "P. & A. Kyriakou" Children's Hospital, Athens, Greece;*

EVALUATION OF C-REACTIVE PROTEIN ON PROGRESSION OF ATHEROSCLEROSIS ON PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

¹Vasiliki Metaxa, ¹Ioannis Skoumas, ¹Christina Chrysohoou, ¹Christos Pitsavos,

²Antigoni Miliou, ¹Evaggelos Oikonomou, ¹Emmanouil Kampaxis,

¹Constantina Masoura, ¹Dimitrios Tousoulis

¹*Lipid Unit, 1st Cardiology Clinic, Hippokrateio Hospital, Greece;*

²*Molecular and Genetics Department, 1st Cardiology Clinic, Hippokrateio Hospital, Greece;*

CLOPIDOGREL BINDS TO LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) AND INHIBITS THE ENZYME ACTIVITY IN PATIENTS WITH AN ACUTE CORONARY SYNDROME

¹Maria Tsoumani, ¹Constantinos Tellis, ²Maria Chatziathanasiadou,

²Antigoni Katsikoudi, ²Vassiliki Kontogianni, ²Andreas Tzakos,

¹Alexandros Tselepis

¹*Atherothrombosis Research Center/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;*

²*Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;*

Sunday, **October 11, 2015**

HYPERLIPIDEMIC NEPHROTIC SYNDROME ASSOCIATED WITH RENAL VEIN THROMBOSIS

¹Elif Gram, ¹Ferhat Ekinici, ¹Mehmet Can Ugur, ¹Cihangir Turemis, ³Emrah Akay,
²Mehmet Tanrisev, ¹Sezgi Kayikcioglu
¹*Izmir Tepecik Education and Research Hospital, Department of Internal Medicine, Turkey;*
²*Izmir Tepecik Education and Research Hospital, Nephrology, Turkey;*
³*Izmir Tepecik Education and Research Hospital, Radiology, Turkey;*

RESISTANCE TO ACTIVATED PROTEIN-C IN PATIENTS WITH EARLY VEIN GRAFT OCCLUSION AFTER CORONARY BYPASS SURGERY

Serdar Payzin, Levent Can, Meral Kayikcioglu, Hakan Kultursay
Ege University Medical School Cardiology Department, Izmir, Turkey;

ANTIPLATELET TREATMENT IN PATIENTS WHO HAVE AN ISCHEMIC STROKE WHILE TAKING ASPIRIN

Konstantinos Tziomalos, Stella Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Vasilios Giampatzis, Maria Tsopozidi, Stella Aggelopoulou, Christos Savopoulos, Apostolos Hatzitolios
First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece;

THE FUNCTIONAL ROLE OF BROWN ADIPOSE TISSUE IN WHOLE-BODY LIPID METABOLISM IN HUMANS

Labros Sidossis
Professor, Department of Internal Medicine-Geriatrics, UT Medical Branch at Galveston, USA, Department of Nutrition and Dietetics, Harokopio University, Athens Greece;

Invited Faculty

Athyros Vassilios

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Catapano Alberico

Professor of Pharmacology, Faculty of Pharmacy, Department of Pharmacological Sciences, University of Milano, Italy

Elisaf Moses

Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece

Ganotakis Emmanuel

Associate Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece

Karagiannis Asterios

Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, "Ippokrateio" Hospital, Thessaloniki, Greece

Kayikcioglu Meral

Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Ege University, Izmir, Turkey

Kiortsis Dimitrios

Professor of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

Kotsis Vassilios

Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Koylan Nevrez

Professor of Cardiology, Faculty of Medicine, Anadolu Medical Center, Gebze, Kocaeli, Turkey

Kultursay Hakan

Professor of Cardiology, Faculty of Medicine, School of Medicine, Ege University, Izmir, Turkey

Lambert Gilles

Associate Professor of Cell Biology, Faculty of Medicine, School of Medical Sciences, University of Nantes, Nantes, France

Liberopoulos Evangelos

Assistant Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece

Mikhailidis Dimitrios

Professor, Head of Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK

Nikolaou Vassilios

Cardiologist, Director, 1st Department of Cardiology, "Korgialeneio-Benakeio" General Hospital of Athens, Athens, Greece

Nilsson Peter

Professor of Clinical Cardiovascular Research, Department of Clinical Sciences, Lund University, Skane University Hospital, Malmo, Sweden

Nordestgaard Borge

Professor in Clinical Biochemistry, Faculty of Medicine, School of Health and Medical Sciences, University of Copenhagen, Chief Physician, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

Ozer Necla

Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Hacettepe University, Ankara, Turkey

Panagiotakos Demosthenes

Professor in Biostatistics - Epidemiology of Nutrition, Department of Nutrition and Dietetics, School of Health Sciences & Education, Harokopeio University of Athens, Athens, Greece

Pitsavos Christos

Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece

Sansoy Vedat

Professor of Cardiology, Institute of Cardiology, University of Istanbul, Istanbul, Turkey

Stabouli Stella

Assistant Professor of Pediatrics, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Hippokraton Hospital of Thessaloniki, Thessaloniki, Greece

Tokgozoglu Lale

Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Hacettepe University, Ankara, Turkey

Tselepis Alexandros

Professor of Biochemistry-Clinical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

Tziomalos Konstantinos

Assistant Professor of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

Ural Dilek

Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Kocaeli University, Kocaeli, Turkey

Zeki Ongen

Professor of Medicine, Department of Cardiology, Cerrahpasha Medical Faculty, Istanbul University, Istanbul, Turkey

General Information

DATE & VENUE

The 2nd Joint Meeting on Lipid, Lipoproteins and Hypolipidaemic Therapy, will be held from **Friday, October 9th to Sunday, October 11th, 2015 in Kos International Convention Center (KICC), Greece.**

Kos International Convention Center (KICC)

Psalidi, 85300 Kos, Greece

Tel: +30 22420 55300, Fax: +30 22420 23590, E-mail: info@kipriotis.gr

REGISTRATION

Registration for the Meeting is free of charge.

OFFICIAL LANGUAGE

The official language of the meeting is English. Simultaneous translation (interpretation) is not provided.

NAME BADGE-SCANNING

All participants, upon confirmation of their registration at the Secretariat, will be provided with a name badge that bears a unique barcode.

It must be clearly understood that barcode badges must be scanned **before entering AND after exiting** the Lecture Hall.

According to the National Organization of Medicines Regulation participation for at least of 60% of the total duration of the scientific programme must be secured and recorded!

Notes:

- It is obligatory for all participants to wear their badges always during the congress.
- Barcode name badge already used for recording attendance cannot be replaced with a second badge.
- Name badges are also necessary for admittance to the social events.
- Badges must be returned to the Secretariat for receiving the Certificate of Attendance.

ACCREDITATION

The Congress has been accredited with **10 C.M.E. Credits** by the Panhellenic Medical Association.

HELLENIC JOURNAL OF ATHEROSCLEROSIS

All abstracts have been published in a special supplement of the **Hellenic Journal of Atherosclerosis** which will be distributed to all participants upon registration along with the course material.

CERTIFICATE OF ATTENDANCE

All registered participants are entitled to receive a Certificate of Attendance. The Certificate will be issued on Sunday, October 11th 2015 by the end of the Scientific Programme and only upon return of the name badge and the completed Evaluation Form at the Secretariat desk.

MOBILE PHONES

Everyone is requested to switch off his/her mobile phone while in session Halls.

LIABILITY AND INSURANCE

The Organizers as well as the Organizing-Administrative Bureau will assume no liability for injuries or losses of any nature incurred by participants and/or accompanying persons, or for the damage, loss or theft of their personal property during the Meeting. Participants are advised to be aware of their own health, travel and personal insurances.

CONTACT

Organizing-Administrative Bureau/Secretariat:



Stavrou Niarchou Avenue, GR 45110 Ioannina, Greece

Tel.: (+30) 26510 68610, Fax: (+30) 26510 68611

E-mail: info@conferre.gr, Website: www.conferre.gr

Oral & Poster Presentations - Information

Please note that all submitted abstracts were reviewed by an independent abstract **Review Committee** that was blinded in regard of authors' names and affiliations. The review, evaluation and final acceptance was based on the **best scoring** as far as work's scientific/clinical importance, results/conclusions & originality is concerned.

Abstract Review Committee:

Coordinator:

Alexandros Tselepis (Greece)

Members:

Vassilios Athyros (Greece)

Moses Elisaf (Greece)

Meral Kayikcioglu (Turkey)

Hakan Kultursay (Turkey)

Evangelos Liberopoulos (Greece)

Zeki Ongen (Turkey)

Necla Ozer (Turkey)

Konstantinos Tziomalos (Greece)

Dilek Ural (Turkey)

Poster Display

Poster Dimensions

should be **100cm height x 80cm width.**

Notes:

- The posters should be prepared in English language.
- Posters will remain mounted for the duration of the Meeting. Authors are requested to mount their posters from the beginning of the scientific program and dismount them by the closing of the program and during the secretariat operating hours.
- Authors must ensure that they will mount their poster on the respective designated space with the corresponding number. The list with the posters and their numbers will be available on a message board near the poster area. Furthermore authors can find and confirm their numbering inside the pages of the Final Programme.

For the Oral Presentation

Duration

Each oral presentation should not exceed **8 minutes**.
It will be followed by 2 minutes discussion.

.....

Oral Presentation session:

Sunday, October 11th 2015 from **08.00** to **09.30**

.....

HELLENIC JOURNAL OF ATHEROSCLEROSIS

All oral and poster presentations have been published in a special supplement of the **Hellenic Journal of Atherosclerosis** which will be distributed to all participants upon registration along with the course material.

Oral & Poster Presentations - List

PP01 - OP01 (ACT1044)

PHARMACOKINETICS OF SELF NANO EMULSION DRUG DELIVERY SYSTEMS FOR THE ORAL ADMINISTRATION OF ROSUVASTATIN CALCIUM

¹Hatice Yesim Karasulu, ²Evren Gundogdu, ³Tugce Turgay, ³Ugur Onsel Turk,

³Sebnem Apaydin, ⁴Ilgin Yidirim Simsir, ⁴Candeger Yilmaz, ³Ercument Karasulu

¹Ege University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Izmir, Turkey;

²Ege University, Faculty of Pharmacy, Radiopharmacy Department, Izmir, Turkey;

³Ege University ARGEFAR Drug Development and Pharmacokinetic Research Center, Izmir, Turkey;

⁴Ege University, Medicine Faculty, Endocrinology Department, Izmir, Turkey;

PP02 - OP02 (ACT1019)

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOMO-FH) IN GREECE: EPIDEMIOLOGICAL DATA FROM 34 PATIENTS

E. Drogari, N. Mavroidis, E. Laios, P. Progias, V. Mollaki

Choremio Research Institute, Metabolic Unit, 1st Department Pediatrics, University of Athens, «Aghia Sofia» Children's Hospital, Athens, Greece;

PP03 - OP03 (ACT1051)

SWITCH TO ROSUVASTATIN VERSUS ADDITION OF EZETIMIBE IN PATIENTS RECEIVING ATORVASTATIN: EFFECT ON URINE 8-ISOPROSTANE LEVELS

Eleftherios Klouras, Constantinos Tellis, Fotios Barkas, Evangelos Liberopoulos, Moses Elisaf, Alexandros Tselepis

¹Department of Internal Medicine, School of Medicine University of Ioannina, Ioannina, Greece;

²Atherothrombosis Research Centre / Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;

PP04 - OP04 (ACT1020)

CHOLESTERYL ESTER STORAGE DISEASE IN GREECE: A RARE INBORN ERROR OF METABOLISM PRESENTING WITH DYSLIPIDAEMIA AND LIVER DISEASE

¹E. Drogari, ¹V. Mollaki, ²H. Christomanou, ³K. Stamatelopoulos, ⁴N. Manolaki

¹Metabolic and Lipid Clinic, 1st Department of Pediatrics, University of Athens, «Aghia Sofia» Children's Hospital, Athens Greece;

²Research Center for Lysosomal and Neurodegenerative Disorder, Athens Greece;

³Department of Internal Medicine, University of Athens, «Alexandras» General Hospital, Athens, Greece;

⁴2nd Department of Pediatrics, NHS, «Aghia Sofia» Children's Hospital, Athens, Greece;

PP05 - OP05 (ACT1022)

RISK FACTORS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE IN CHILDREN AND ADOLESCENTS WITH CHRONIC KIDNEY DISEASE: A SINGLE CENTRE PROSPECTIVE STUDY

¹Styliani Drapaniotti, ²George Karapostolakis, ³Varvara Askiti, ²Marina Vakaki, ³Andromachi Mitsioni, ³Maria Mila, ³Constantinos Stefanidis, ¹Anastasia Garoufi
¹Lipid Outpatient Unit, ²2nd Department of Pediatrics, Athens University, Greece;
²Radiology Department, "P. & A. Kyriakou" Children's Hospital, Athens, Greece;
³Unit of Pediatric Nephrology, "P. & A. Kyriakou" Children's Hospital, Athens, Greece;

PP06 - OP06 (ACT1058)

EVALUATION OF C-REACTIVE PROTEIN ON PROGRESSION OF ATHEROSCLEROSIS ON PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

¹Vasiliki Metaxa, ¹Ioannis Skoumas, ¹Christina Chrysohoou, ¹Christos Pitsavos, ²Antigoni Miliou, ¹Evaggelos Oikonomou, ¹Emmanouil Kampaxis, ¹Constantina Masoura, ¹Dimitrios Tousoulis
¹Lipid Unit, ¹1st Cardiology Clinic, Hippokrateio Hospital, Greece;
²Molecular and Genetics Department, ¹1st Cardiology Clinic, Hippokrateio Hospital, Greece;

PP07 - OP07 (ACT1033)

CLOPIDOGREL BINDS TO LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) AND INHIBITS THE ENZYME ACTIVITY IN PATIENTS WITH AN ACUTE CORONARY SYNDROME

¹Maria Tsoumani, ¹Constantinos Tellis, ²Maria Chatziathanasiadou, ²Antigoni Katsikoudi, ²Vassiliki Kontogianni, ²Andreas Tzakos, ¹Alexandros Tselepis
¹Atherothrombosis Research Center/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;
²Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;

PP08 - OP08 (ACT1031)

HYPERLIPIDEMIC NEPHROTIC SYNDROME ASSOCIATED WITH RENAL VEIN THROMBOSIS

¹Elif Gram, ¹Ferhat Ekinici, ¹Mehmet Can Ugur, ¹Cihangir Turemis, ³Emrah Akay, ²Mehmet Tanrisev, ¹Sezgi Kayikcioglu
¹Izmir Tepecik Education and Research Hospital, Department of Internal Medicine, Turkey;
²Izmir Tepecik Education and Research Hospital, Nephrology, Turkey;
³Izmir Tepecik Education and Research Hospital, Radiology, Turkey;

PP09 - OP09 (ACT1046)

RESISTANCE TO ACTIVATED PROTEIN-C IN PATIENTS WITH EARLY VEIN GRAFT OCCLUSION AFTER CORONARY BYPASS SURGERY

Serdar Payzin, Levent Can, Meral Kayikcioglu, Hakan Kultursay
Ege University Medical School Cardiology Department, Izmir, Turkey;

PP10 - OP10 (ACT1029)

ANTIPLATELET TREATMENT IN PATIENTS WHO HAVE AN ISCHEMIC STROKE WHILE TAKING ASPIRIN

Konstantinos Tziomalos, Stella Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Vasilios Giampatzis, Maria Tsopozidi, Stella Aggelopoulou, Christos Savopoulos, Apostolos Hatzitolios
First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece;

PP11 (ACT1047)

IDENTIFICATION OF LIPID BIOMARKERS OF THE PRESENCE AND PROGRESSION OF ISCHEMIC HEART DISEASE BY NMR-BASED LIPIDOMIC ANALYSIS OF RED BLOOD CELL MEMBRANES

¹Ioanna Kastani, ¹Christina Kostara, ²John Baltogiannis, ²Vasileios Tsimihodimos, ²John Goudevenos, ¹Eleni Bairaktari, ²Moses Elisaf
¹*Laboratory of Clinical Chemistry, Medical School, University of Ioannina, Ioannina, Greece;*
²*Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece;*

PP12 (ACT1006)

HYPERLIPIDEMIA IN NEPHROTI SYNDROME

Ezelfunanya Bertha
Zaporozhye State Medical University, Zaporozhye, Ukraine;

PP13 (ACT1007)

RISK FACTORS OF ATHEROSCLEROSIS IN NEPHROTIC SYNDROME

Ezelfunanya Bertha
Zaporozhye State Medical University, Zaporozhye, Ukraine;

PP14 (ACT1010)

BURDEN OF ISCHEMIC CARDIOVASCULAR DISEASE AMONG INDIVIDUALS WITH AND WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA ATTENDING A LIPID CLINIC

Fotios Barkas, Eleftherios Klouras, Theodora Dimitriou, Elena Petrou, Moses Elisaf, Evangelos Liberopoulos
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece;

PP15 (ACT1011)

DIFFERENCES OF METABOLIC PROFILE BETWEEN INDIVIDUALS WITH AND WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA ATTENDING A LIPID CLINIC

Fotios Barkas, Eleftherios Klouras, Theodora Dimitriou, Elena Petrou, Evangelos Liberopoulos, Moses Elisaf

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece;

PP16 (ACT1012)

INDIVIDUALS WITH FAMILIAL HYPERCHOLESTEROLEMIA ARE UNDERTREATED EVEN IN A SETTING OF A LIPID CLINIC

Fotios Barkas, Evangelos Liberopoulos, Eleftherios Klouras, Theodora Dimitriou, Moses Elisaf

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece;

PP17 (ACT1013)

WHICH FACTORS INCREASE THE PREVALENCE OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITH FAMILIAL HYPERCHOLESTEROLEMIA? EVIDENCE FROM A LIPID CLINIC

Fotios Barkas, Eleftherios Klouras, Theodora Dimitriou, Moses Elisaf, Evangelos Liberopoulos

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece;

PP18 (ACT1014)

MAJOR LIPOPROTEINS AND ACUTE ISCHEMIC STROKE SEVERITY AND IN-HOSPITAL OUTCOME

Konstantinos Tziomalos, Stella Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Vasilios Giampatzis, Stella-Maria Angelopoulou, Maria Tsopezidi, Christos Savopoulos, Apostolos Hatzitolios

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece;

PP19 (ACT1015)

DYSBETALIPOPROTEINEMIA; A CHALLENGING DIAGNOSIS

¹Anastazia Kei, ²George Miltiadous, ³Eleni Bairaktari, ²Marilena Hadjivassiliou, ²Marios Cariolou, ¹Moses Elisaf

¹*Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece;*

²*Department of Cardiovascular Genetics and the Laboratory of Forensic Genetics, Cyprus Institute of Neurology and Genetics, Nicosia Cyprus;*

³*Department of Biochemistry, University of Ioannina Medical School, Ioannina, Greece;*

PP20 (ACT1016)

A LOW-FAT, LOW-CALORIC DIET ENHANCES THE HYPOLIPIDEMIC EFFECT OF HYPOLIPEMIC MEDICATION IN OVERWEIGHT PATIENTS¹Adamantios Bourdakis, ²Dimitra Kagiafa, ¹Stamatis Papadatos¹Internal Medicine, ²Internal Medicine Clinic and External Clinic of Lipidology and Obesity, General Hospital of Trikala, Greece;²Nutritionist-Dietitian, Department of Clinical Nutrition, Greece;

PP21 (ACT1017)

ADDITION OF EZETIMIBE IN PATIENTS RECEIVING ATORVASTATIN: EFFECTS ON LIPID AND GLYCEMIC PROFILEEleftherios Klouras, Fotios Barkas, Evangelos Liberopoulos, Moses Elisaf

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece;

PP22 (ACT1018)

VASCULAR DISEASE PRESENTS AS ORTNER SYNDROME¹Aikaterini Drylli, ²Aikaterini Zotou, ³Michalis Tsamatsoulis,³Victor Panagiotakopoulos, ³Christos Charitos¹ENT Clinic, General Hospital Neaslonias "Konstantopouleio", Athens, Greece;²Plastic Surgery Clinic, General Hospital Athens "Evangelismos", Athens, Greece;³Heart and Thorax Surgery Clinic, General Hospital Athens "Evangelismos", Athens, Greece;

PP23 (ACT1021)

THE IMPORTANCE OF MEAN PLATELET VOLUME IN CARDIOVASCULAR DISEASE AND MORTALITY IN HEMODIALYSIS PATIENTS¹Eleni Paschou, ²Sotirios Vasileiou, ³Eleni Gavriilaki, ²Efthimios Pappas,²Evaggelia Pipereli, ²Christos Dontsos, ²Nikos Sabanis¹Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece;²Nephrology Division, General Hospital of Pella, Edessa, Greece;³Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece;

PP24 (ACT1023)

CARDIOVASCULAR CONSEQUENCES LINKED TO NON-ALCOHOLIC FATTY LIVER DISEASE PRESENCE IN HEMODIALYSIS PATIENTS¹Nikos Sabanis, ¹Sotirios Vasileiou, ²Eleni Gavriilaki, ³Eleni Paschou¹Nephrology Department, General Hospital of Pella, Edessa, Greece;²Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece;³Department of General Practice & Family Medicine, General Hospital of Pella, Edessa, Greece;

PP25 (ACT1024)

A RARE CAUSE OF SECONDARY HYPERTENSION: SCLERODERMA RENAL CRISIS

¹Mehmet Can Ugur, ¹Ferhat Ekinici, ¹Elif Gram, ¹Sezgi Kayikcioglu, ²Hulya Colak, ³Cengiz Ceylan, ⁴Zevcet Yilmaz, ⁵Tugba Karadeniz

¹Izmir Tepecik Education and Research Hospital, Department of Internal Medicine, Turkey;

²Izmir Tepecik Education and Research Hospital, Nephrology, Turkey;

³Izmir Tepecik Education and Research Hospital, Hematology, Turkey;

⁴Izmir Tepecik Education and Research Hospital, Rheumatology, Turkey;

⁵Izmir Tepecik Education and Research Hospital, Department of Pathology, Turkey;

PP26 (ACT1025)

HYPERTENSIVE AND NORMOKALEMIC PRIMARY ALDOSTERONISM IN A GERIATRIC PATIENT WITH AN ALDOSTERONE-PRODUCING ADENOMA

¹Ferhat Ekinici, ¹Mehmet Can Ugur, ¹Utku Erdem Soyaltin, ¹Elif Gram, ¹Faruk Elyigit, ¹Deniz Yildirim, ¹Sezgi Kayikcioglu, ²Ebru Cakir, ¹Harun Akar

¹Izmir Tepecik Education and Research Hospital, Department of Internal Medicine, Turkey;

²Izmir Tepecik Education and Research Hospital, Department of Pathology, Turkey;

PP27 (ACT1026)

UNFAVOURABLE LIPID PROFILE IS CORRELATED WITH PLATELET TOLL- LIKE RECEPTOR EXPRESSION IN ACUTE CORONARY SYNDROME

¹Duygu Kocyigit, ²Kadri Murat Gurses, ³Muhammed Ulvi Yalcin, ⁴Hande Canpinar, ⁴Dicle Guc, ¹Kudret Aytemir, ¹Necla Ozer, ¹Lale Tokgozoglu

¹Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey;

²Department of Cardiology, Konya Training and Research Hospital, Konya, Turkey;

³Department of Cardiology, Hakkari State Hospital, Hakkari, Turkey;

⁴Hacettepe University Cancer Institute, Basic Oncology Department, Ankara, Turkey;

PP28 (ACT1027)

ASSOCIATION BETWEEN TYPE 2 DIABETES MELLITUS AND LONG-TERM FUNCTIONAL OUTCOME OF PATIENTS DISCHARGED AFTER ACUTE ISCHEMIC STROKE

Konstantinos Tziomalos, Stella Bouziana, Marianna Spanou, Maria Papadopoulou, Vasilios Giampatzis, Vasiliki Dourliou, Stavroula Kostaki, Maria Tsopozidi, Christos Savopoulos, Apostolos Hatzitolios
First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece;

PP29 (ACT1028)

ASSOCIATION BETWEEN BODY MASS INDEX AND THE EFFECT OF ANTIHYPERTENSIVE TREATMENT ON THE LONG-TERM OUTCOME OF PATIENTS WITH ACUTE ISCHEMIC STROKE

Konstantinos Tziomalos, Stella Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Vasilios Giampatzis, Stella Aggelopoulou, Filitsa Konstantara, Christos Savopoulos, Apostolos Hatzitolios
First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece;

PP30 (ACT1030)

LESION CHARACTERISTICS IN YOUNGER ADULTS WITH ACUTE CORONARY SYNDROME

¹Oner Ozdogan, ¹Ahmet Sayin, ¹Cenk Ekmekci, ²Mustafa Yildirim

¹*Tepecik Training and Research Hospital, Department of Cardiology, Turkey;*

²*Tepecik Training and Research Hospital, Department of Internal Medicine, Turkey;*

PP31 (ACT1032)

ASSOCIATION BETWEEN SERUM URIC ACID LEVELS AND LEFT VENTRICULAR HYPERTROPHY IN ESSENTIAL HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE

^{1,4}Dafni Koumoutsea, ^{1,4}Vasileios German, ²Christina Soitou,

³Damianos Aslanoglou, ⁴Ioannis Griveas, ⁵Konstantinos Xenakis,

⁵Spyridon Hadjisaltas, ⁴Anastasios Galinas, ⁵Panagiotis Kotileas,

⁴Georgios Stavgiannoudakis

¹*Sector of Internal Medicine 401 General Army Hospital of Athens, Greece;*

²*Internal Medicine Department of Kos Hospital, Greece;*

³*Health Center of Patmos, Greece;*

⁴*Division of Renal Medicine 417 Veterans Affairs Hospital of Athens (NIMTS), Greece;*

⁵*Division of Cardiology and Cardiovascular Medicine 401 General Army Hospital of Athens, Greece;*

PP32 (ACT1034)

SUDDEN DEATHS CAUSED BY THE LACK OF HEPARIN AND MYOCARD INFARCTUS

Neriman Karabasoglu

Araf Surgery Center, Istanbul, Turkey;

PP33 (ACT1035)

ASSOCIATION BETWEEN MICROALBUMINURIA OF DIABETIC NEPHROPATHY AND STRUCTURAL CHANGES IN ARTERIAL VESSELS^{1,4}Dafni Koumoutsea, ^{1,4}Vasileios German, ²Christina Soitou,³Damianos Aslanoglou, ⁴Ioannis Griveas, ⁵Konstantinos Xenakis,⁵Christoforos Kotoulas, ⁴Anastasios Galinas, ⁵Panagiotis Kotileas,⁴Georgios Stavgianoudakis¹Sector of Internal Medicine 401 General Army Hospital of Athens, Greece;²Internal Medicine Department of Kos Hospital, Greece;³Health Center of Patmos, Greece;⁴Division of Renal Medicine 417 Veterans Affairs Hospital of Athens (NIMTS), Greece;⁵Division of Cardiology and Cardiovascular Medicine 401 General Army Hospital of Athens, Greece;

PP34 (ACT1036)

DEVELOPMENT OF METABOLIC SYNDROME IN HOSPITALIZED PATIENTS OF PSYCHARGOS DEPARTMENT OF GENERAL HOSPITAL OF NAFPLIOP. Heras, M. Koutroubi, G. A. Sarri, I. Georgopoulos*Department of Internal Medicine, General Hospital of Nafplio, Nafplio, Greece;*

PP35 (ACT1037)

LOW DENSITY LIPOPROTEIN (L.D.L.) LEVELS IN MALE AND FEMALE PATIENTS WITH ACUTE CORONARY SYNDROMEP. Heras, M. Koutroubi, G. A. Sarri, I. Georgopoulos*Department of Internal Medicine, General Hospital of Nafplio, Nafplio, Greece;*

PP36 (ACT1038)

PRESYMPTOMATIC GROUP TESTING FOR HYPERCHOLESTEROLEMIA IN MALE POPULATION OF GREEK WORKERSP. Heras, M. Koutroubi, G. A. Sarri, I. Georgopoulos*Department of Internal Medicine, General Hospital of Nafplio, Nafplio, Greece;*

PP37 (ACT1039)

STUDY OF THE RELATIONSHIP BETWEEN HDL LEVELS OF PATIENTS WITH DIABETES TYPE II AND VARIOUS PARAMETERSP. Heras, M. Koutroubi, G. A. Sarri, I. Georgopoulos*Department of Internal Medicine, General Hospital of Nafplio, Nafplio, Greece;*

PP38 (ACT1040)

THE BENEFICIAL INFLUENCE OF THE STATIN THERAPY IN HYPERTENSIVE PATIENTS WITH ACUTE CORONARY SYNDROMEP. Heras, M. Koutroubi, G. A. Sarri, I. Georgopoulos*Department of Internal Medicine, General Hospital of Nafplio, Nafplio, Greece;*

PP39 (ACT1041)

HBA1C LEVELS AND THE RISK OF TACHYARRHYTHMIA IN DIABETIC PATIENTS WITH PREVIOUSLY KNOWN PAROXYSMAL ATRIAL FIBRILLATION¹Alexandra Sianni, ²Asimina Ganotopoulou, ³Petros Krezias, ¹Ioannis Matsoukis,¹Constantina Kostaki, ¹Polichronis Paraskevas, ¹Aggelos Asimis,¹Panagiotis Milonas, ⁴Lamprini Skorda, ¹Ioannis Liouris¹Konstantopoulou General Hospital, Pathology Department, Athens, Greece;²Private Pathologist, Piraeus, Greece;³Private Cardiologist, Athens, Greece;⁴Erithros Stavros Hospital, Pathology Department, Athens, Greece;

PP40 (ACT1042)

PARAOXONASE 1 Q192R POLYMORPHISM AND EVOLUTION OF LEFT VENTRICULAR FUNCTION IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS¹Evangelia Dounousi, ²Ioanna Bouba, ³Kostas Pappas, ²Ioannis Georgiou,⁴Alexandros Tselepis, ⁵Moses Elisaf, ⁶Dimitris Tsakiris, ¹Kostas Siamopoulos¹Department of Nephrology, University Hospital of Ioannina, Greece;²Laboratory of Human Reproductive Genetics, Medical School University of Ioannina, Greece;³Department of Cardiology, University Hospital of Ioannina, Greece;⁴Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece;⁵Department of Internal Medicine, University Hospital of Ioannina, Greece;⁶Department of Nephrology, General Hospital "Papageorgiou" of Thessaloniki, Greece;

PP41 (ACT1043)

THE IMPACT OF SERUM TRIGLYCERIDES ON THE RELATIONSHIP BETWEEN RETINOL-BINDING PROTEIN 4 AND APOLIPOPROTEIN-B CONTAINING LIPOPROTEINS¹Georgios A. Christou, ²Constantinos C. Tellis, ³Moses S. Elisaf,²Alexandros D. Tselepis, ¹Dimitrios N. Kiortsis¹Laboratory of Physiology, Medical School, University of Ioannina, Ioannina, Greece;²Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece;³Second Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece;

PP42 (ACT1045)

IN HOSPITAL AND LONG TERM FOLLOW-UP OF PATIENTS ADMITTED WITH AN ACUTE CORONARY SYNDROME FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERYLevent Can, Serdar Payzin, Meral Kayikcioglu, Oğuz Yavuzgil, Hakan Kultursay
Ege University Medical School Cardiology Dept, Turkey;

PP43 (ACT1048)

THE ROLE OF APELIN IN ATHEROSCLEROSIS

Dimochristos Papadimitriou, Areti Katsouda, Maria Mironidou-Tzouveleki
A' Laboratory of Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Greece;

PP44 (ACT1049)

RESOLUTION OF NON-ALCOHOLIC STEATOHEPATITIS BY ROSUVASTATIN MONOTHERAPY IN PATIENTS WITH METABOLIC SYNDROME

Kostas Kargiotis, ¹Vasilios G. Athyros, ¹Niki Katsiki, ¹Olga Giouleme,
¹Asterios Karagiannis, ²Dimitri P. Mikhailidis

¹ Internal Medicine AUTH;

² Department of Clinical Biochemistry Royal Free Campus, University College London Medical School (UCL), London, UK;

PP45 (ACT1050)

PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH ESSENTIAL HYPERTENSION IN CRETE

John Papadakis, George Vrentzos, Eirini Lioudaki, Emmanuel Ganotakis
Hypertension Clinic, University Hospital of Crete, Heraklion, Greece;

PP46 (ACT1052)

SWITCHING TO ROSUVASTATIN OR ADDING EZETIMIBE IN DYSLIPIDEMIC PATIENTS RECEIVING ATORVASTATIN, SIGNIFICANTLY REDUCE PLASMA APOB/LP-PLA2 LEVELS

Eleftherios Klouras, ²Constantinos Tellis, ¹Fotios Barkas,

¹Evangelos Liberopoulos, ¹Moses Elisaf, ²Alexandros Tselepis

¹Department of Internal Medicine, School of Medicine University of Ioannina, Greece;

²Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece;

PP47 (ACT1053)

LIPIDS AND BIPOLAR DISORDER

^{1,2}Vasiliki Mamakou, ³Nikolaos Tentolouris, ⁴Fragiskos Gonidakis,

⁴Vasileios Kontaxakis, ⁵Anastasia Thanopoulou

¹Internal Medicine, Dromokaiteio Psychiatric Hospital, Athens, Greece;

²National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece;

³First Department of Propaedeutic and Internal Medicine, Athens University Medical School, Laiko General Hospital, Athens, Greece;

⁴1st Department of Psychiatry, Athens University Medical School, Athens, Greece;

⁵Diabetes Centre, 2nd Department of Internal Medicine, National University of Athens, Hippokraton General Hospital, Athens, Greece;

PP48 (ACT1054)

EVALUATION OF INFLAMMATORY MARKERS IN FAMILIAL HYPERCHOLESTEROLEMIA

¹Vasiliki Metaxa, ¹Christos Pitsavos, ¹Ioannis Skoumas, ¹Christina Chrysohoou, ²Antigoni Miliou, ¹Evangelos Oikonomou, ¹Constantina Masoura, ¹Emmanouil Kampaxis, ¹Christodoulos Stefanadis, ¹Dimitrios Tousoulis
¹Lipid Unit, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;
²Molecular and Genetics Department, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;

PP49 (ACT1055)

COMPLIANCE ON TREATMENT STRATEGY AND CARDIOVASCULAR DISEASE INCIDENCE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

Vasiliki Metaxa, Ioannis Skoumas, Christina Chrysohoou, Evangelos Oikonomou, Constantina Masoura, Emmanouil Kampaxis, Efi Tseysekou, Christodoulos Stefanadis, Christos Pitsavos, Dimitrios Tousoulis
¹Lipid Unit, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;

PP50 (ACT1056)

THE IMPACT OF LOW DENSITY LIPOPROTEIN RECEPTOR(LDLR) GENE MUTATION ON INCIDENCE OF PREMATURE CARDIOVASCULAR DISEASE, IN FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS

¹Vasiliki Metaxa, ¹Christos Pitsavos, ¹Ioannis Skoumas, ¹Christina Chrysohoou, ²Antigoni Miliou, ¹Evangelos Oikonomou, ¹Emmanouil Kampaxis, ¹Constantina Masoura, ¹Christodoulos Stefanadis, ¹Dimitrios Tousoulis
¹Lipid Unit, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;
²Molecular and Genetics Department, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;

PP51 (ACT1057)

THE IMPACT OF LOW DENSITY LIPOPROTEIN RECEPTOR(LDLR) GENE MUTATION ON CAROTID INTIMA MEDIA THICKNESS, IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

¹Vasiliki Metaxa, ¹Christos Pitsavos, ¹Ioannis Skoumas, ¹Christina Chrysohoou, ²Antigoni Miliou, ¹Evangelos Oikonomou, ¹Emmanouil Kampaxis, ¹Constantina Masoura, ¹Christodoulos Stefanadis, ¹Dimitrios Tousoulis
¹Lipid Unit, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;
²Molecular and Genetics Department, ^{1st} Cardiology Clinic, Hippokrateio Hospital, Greece;

Sponsors/Acknowledgements

Aegerion[®]
Pharmaceuticals

AMGEN[®]



 **Mylan**
Seeing
is believing



SANOFI

The Organizers would also like to thank the **Municipal Organization Of Culture, Sports and Nursery Centers of Kos** for its kind support and contribution

INEGY™
(ezetimibe/simvastatin)

EZETROL™
(ezetimibe)



Για περισσότερες συνταγογραφικές πληροφορίες συμβουλευτείτε την Περίληψη Χαρακτηριστικών των Προϊόντων.



Υπεύθυνος Άδειας Κυκλοφορίας
MSD Α.Φ.Β.Ε.Ε
Αγ. Δημητρίου 63, 174 56 Άλιμος,
Αθήνα, Τηλ.: 210 9897300
www.msd.gr



Συνπροώθηση από την εταιρεία:

BIANEX Α.Ε. ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

LICENSEE / DISTRIBUTOR OF MERCK SHARP & DOHME,
Division of MERCK & Co., Inc., Whitehouse Station, N.J., USA

Γραφεία Επιστημονικής Ενημέρωσης

ΑΘΗΝΑ: Οδός Τατσιού, 146 71 Ν. Ερυθραία, Τηλ.: 210 8009111

• E-mail: mailbox@vianex.gr • INTERNET: <http://www.vianex.gr>

• ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδήμου 113, Κόμβος Μακρυγιάννη,

Εύσμος Θεσσαλονίκης, ΤΚ 56224, Τηλ: 2310 833893


• ΠΑΤΡΑ: Μαιζώνος 131, Τηλ.: 2610 221397



Xarelto®

rivaroxaban

15mg & 20mg



Bayer

Κάτοχος της άδειας κυκλοφορίας:
Bayer Pharma AG, 13342 Berlin, Γερμανία
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ABEE, Σωρού
18-20, 151 25 Μαρούσι,
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Κύπρο: Novagem Ltd,
Τηλ: 00357 22483858

Τμήμα Επιστημονικής Ενήμερωσης
Τηλ: +30 210 6187742, Fax: +30 210 6187522
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπτώθησης



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,
Τηλ: 210 6039326 - 9, Fax: 210 6039300
ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα,
Τηλ: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ: 2310 459920 - 1, Fax: 2310 459269

LOGO 04/09/2014/0371

Πριν τη συνταγογράφηση συμβουλευθείτε την Περιλήψη των Χαρακτηριστικών του Προϊόντος που διατίθεται στο εκθετήριο

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»